BACKGROUND AND OBJECTIVES: Neointimal hyperplasia is the major cause of vascular access failure in hemodialysis patients. Statins reduce neointimal hyperplasia in experimental models, which may reduce access failure. The study presented here evaluated whether vascular access outcomes are superior in patients receiving statin therapy than in those not on statins. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A prospective computerized vascular access database was retrospectively queried to determine the access outcomes of 601 patients receiving an upper-arm fistula or graft at a single large dialysis center. RESULTS: Primary fistula failure was observed in 37% of patients on statin therapy versus 38% not on statin therapy. Primary graft failure occurred in 20% of patients on statin therapy versus 14% not on statin therapy. A multiple variable logistic regression analysis including statin use, diabetes, coronary artery disease, peripheral artery disease, sex, and age found that only sex predicted primary fistula failure and graft failure. After excluding primary failures, cumulative fistula survival was similar for patients with or without statin therapy (hazard ratio [HR] 1.26; 95% confidence interval [CI] 0.76 to 2.16). Likewise, cumulative graft survival was similar for statin therapy versus no statin therapy (HR 0.88; 95% CI 0.59 to 1.32). Using a multivariable survival analysis model to predict cumulative fistula survival, only age predicted fistula failure (HR 1.21 per decade; 95% CI 1.02 to 1.44). None of the variables in this model predicted cumulative graft survival. CONCLUSIONS: Statin therapy is not associated with improved fistula or graft outcomes in patients with chronic kidney disease.
BACKGROUND AND OBJECTIVES: Neointimal hyperplasia is the major cause of vascular access failure in hemodialysis patients. Statins reduce neointimal hyperplasia in experimental models, which may reduce access failure. The study presented here evaluated whether vascular access outcomes are superior in patients receiving statin therapy than in those not on statins. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A prospective computerized vascular access database was retrospectively queried to determine the access outcomes of 601 patients receiving an upper-arm fistula or graft at a single large dialysis center. RESULTS:Primary fistula failure was observed in 37% of patients on statin therapy versus 38% not on statin therapy. Primary graft failure occurred in 20% of patients on statin therapy versus 14% not on statin therapy. A multiple variable logistic regression analysis including statin use, diabetes, coronary artery disease, peripheral artery disease, sex, and age found that only sex predicted primary fistula failure and graft failure. After excluding primary failures, cumulative fistula survival was similar for patients with or without statin therapy (hazard ratio [HR] 1.26; 95% confidence interval [CI] 0.76 to 2.16). Likewise, cumulative graft survival was similar for statin therapy versus no statin therapy (HR 0.88; 95% CI 0.59 to 1.32). Using a multivariable survival analysis model to predict cumulative fistula survival, only age predicted fistula failure (HR 1.21 per decade; 95% CI 1.02 to 1.44). None of the variables in this model predicted cumulative graft survival. CONCLUSIONS: Statin therapy is not associated with improved fistula or graft outcomes in patients with chronic kidney disease.
Authors: R E Law; S Goetze; X P Xi; S Jackson; Y Kawano; L Demer; M C Fishbein; W P Meehan; W A Hsueh Journal: Circulation Date: 2000-03-21 Impact factor: 29.690
Authors: P Roy-Chaudhury; B S Kelly; M A Miller; A Reaves; J Armstrong; N Nanayakkara; S C Heffelfinger Journal: Kidney Int Date: 2001-06 Impact factor: 10.612
Authors: Bradley S Dixon; Gerald J Beck; Miguel A Vazquez; Arthur Greenberg; James A Delmez; Michael Allon; Laura M Dember; Jonathan Himmelfarb; Jennifer J Gassman; Tom Greene; Milena K Radeva; Ingemar J Davidson; T Alp Ikizler; Gregory L Braden; Andrew Z Fenves; James S Kaufman; James R Cotton; Kevin J Martin; James W McNeil; Asif Rahman; Jeffery H Lawson; James F Whiting; Bo Hu; Catherine M Meyers; John W Kusek; Harold I Feldman Journal: N Engl J Med Date: 2009-05-21 Impact factor: 91.245
Authors: S Bellosta; F Bernini; N Ferri; P Quarato; M Canavesi; L Arnaboldi; R Fumagalli; R Paoletti; A Corsini Journal: Atherosclerosis Date: 1998-04 Impact factor: 5.162
Authors: Ivan D Maya; Jeremy C O'Neal; Carlton J Young; Jill Barker-Finkel; Michael Allon Journal: Clin J Am Soc Nephrol Date: 2008-10-22 Impact factor: 8.237
Authors: Juan C Duque; Marwan Tabbara; Laisel Martinez; Jose Cardona; Roberto I Vazquez-Padron; Loay H Salman Journal: Am J Kidney Dis Date: 2016-10-27 Impact factor: 8.860
Authors: Jie Cui; Chase W Kessinger; Harkamal S Jhajj; Madeleine S Grau; Sanjay Misra; Peter Libby; Jason R McCarthy; Farouc A Jaffer Journal: J Am Soc Nephrol Date: 2020-03-09 Impact factor: 10.121
Authors: William Herrington; Jonathan Emberson; Natalie Staplin; Lisa Blackwell; Bengt Fellström; Robert Walker; Adeera Levin; Lai Seong Hooi; Ziad A Massy; Vladimir Tesar; Christina Reith; Richard Haynes; Colin Baigent; Martin J Landray Journal: Clin J Am Soc Nephrol Date: 2014-03-13 Impact factor: 8.237